There is good evidence that angiogenesis plays a central role in cervical cancer pathogenesis, suggesting a strong rationale for adding anti-angiogenesis agents to chemotherapeutic agents for the treatment of this disease.
Lynette A. Denny, MD, PhD
Advertisement
Articles by Lynette A. Denny, MD, PhD
Advertisement
Latest Updated Articles
- Questions We Should Be Asking About Bevacizumab for Cervical Cancer
Published: May 15th 2015 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
Progress in the Treatment of Advanced-Stage Classical Hodgkin Lymphoma in the PET-Adapted Era
2
Zipalertinib Yields Early Activity in EGFR+ NSCLC CNS Metastasis Population
3
CRT Does Not Improve RFS/OS, Confers High-Grade Toxicity in Cervical Cancer
4
ctDNA Status May Determine Adjuvant Immunotherapy Benefit in MIBC
5
